Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

Benjamin Z Leder, Carol Zapalowski, Ming-Yi Hu, Gary Hattersley, Nancy E Lane, Andrea J Singer, Robin K Dore, Benjamin Z Leder, Carol Zapalowski, Ming-Yi Hu, Gary Hattersley, Nancy E Lane, Andrea J Singer, Robin K Dore

Abstract

In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and significantly increased bone mineral density (BMD) versus placebo regardless of baseline risk factors. Women from the abaloparatide and placebo groups who completed ACTIVE were eligible for ACTIVExtend (NCT01657162), in which all enrollees received sequential, open-label monotherapy with alendronate 70 mg once weekly for up to 24 months. This prespecified analysis evaluated whether fracture risk reductions and bone mineral density (BMD) gains associated with abaloparatide during ACTIVE persisted through the full 43-month ACTIVE-ACTIVExtend study period in nine prespecified baseline risk subgroups. Baseline risk subgroups included BMD T-score at the lumbar spine, total hip, and femoral neck (≤ - 2.5 versus > - 2.5 and ≤ -3.0 versus > - 3.0), history of nonvertebral fracture (yes/no), prevalent vertebral fracture (yes/no), and age (<65 versus 65 to <75 versus ≥75 years). Forest plots display treatment effect. Treatment-by-subgroup interactions were tested using the Breslow-Day test, Cox proportional hazards model, and ANCOVA model. After the combined ACTIVE-ACTIVExtend study period, reductions in relative risk for new vertebral, nonvertebral, clinical, and major osteoporotic fractures were greater among patients in the abaloparatide/alendronate group than among those in the placebo/alendronate group across all nine baseline risk subgroups. BMD gains at the lumbar spine, total hip, and femoral neck were greater in the abaloparatide/alendronate group versus the placebo/alendronate group. No clinically meaningful interaction between treatment assignment and any baseline risk variable was observed. The sequence of abaloparatide for 18 months followed by alendronate for up to 24 months appears to be an effective treatment option for a wide range of postmenopausal women at risk for osteoporotic fractures. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.

Keywords: ABALOPARATIDE; BASELINE RISK SUBGROUPS; BONE MINERAL DENSITY; FRACTURE PREVENTION; POSTMENOPAUSAL OSTEOPOROSIS.

© 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
New vertebral fracture risk reduction for abaloparatide/alendronate versus placebo/alendronate by prespecified subgroup. ABL = abaloparatide; ALN = alendronate; BMD = bone mineral density; CI = confidence interval; mITT = modified intent‐to‐treat; PBO = placebo; RR = risk ratio.
Figure 2
Figure 2
Nonvertebral fracture risk reduction for abaloparatide/alendronate versus placebo/alendronate by prespecified subgroup. ABL = abaloparatide; ALN = alendronate; BMD = bone mineral density; CI = confidence interval; HR = hazard ratio; PBO = placebo. aNo p value adjustment was made for multiple comparisons.
Figure 3
Figure 3
(A) Percent change from baseline to month 43 in BMD at the lumbar spine by prespecified subgroup. (B) Percent change from baseline to month 43 in total hip BMD by prespecified subgroup. ABL = abaloparatide; ALN = alendronate; BMD = bone mineral density; CI = confidence interval; LSM = least squares mean; PBO = placebo. (C) Percent change from baseline to month 43 in BMD at the femoral neck by prespecified subgroup. ABL = abaloparatide; ALN = alendronate; BMD = bone mineral density; CI = confidence interval; LSM = least squares mean; PBO = placebo. aNo p value adjustment was made for multiple comparisons.

References

    1. Radius Health, Inc. Tymlos (abaloparatide) [prescribing information] . Waltham, MA: Radius Health, Inc.; 2017. Updated October 2018. Available at: . Accessed 22 January 2019.
    1. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33.
    1. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. Effects of abaloparatide‐SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32(1):17–23.
    1. McCloskey EV, Johansson H, Oden A, et al. The effect of abaloparatide‐SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res. 2017;32(8):1625–31.
    1. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–57.
    1. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1‐84) for osteoporosis. N Engl J Med. 2005;353(6):555–5.
    1. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA‐switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–55.
    1. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726–36.
    1. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(1):18–23.
    1. Nagano T, Shiraki M, Sugimoto T, et al. Once‐weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once‐Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab. 2014;32:441–6.
    1. Eastell R, Black DM, Boonen S, et al. Effect of once‐yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009;94(9):3215–25.
    1. McClung MR, Boonen S, Törring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211–8.
    1. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.
    1. McClung MR, Williams GC, Hattersley G, et al. Geography of fracture incidence in postmenopausal women with osteoporosis treated with abaloparatide. Calcif Tissue Int. 2018;102(6):627–33.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir